Biotechnology company GeoVax Labs has expanded its intellectual property protection for Gedeptin®, a promising cancer therapy platform, through a newly allowed U.S. patent covering an innovative treatment approach for solid tumors.
The patent describes a unique therapeutic method involving three key steps: direct intratumoral administration of an adenoviral vector, local prodrug administration, and targeted radiation therapy. This strategy aims to generate localized cytotoxic activity within tumor microenvironments while minimizing systemic side effects.
The newly protected approach could potentially treat multiple cancer types, including glioblastoma, breast, prostate, head and neck, glioma, and lung cancers. By focusing on targeted delivery, the method represents a significant advancement in precision oncology.
GeoVax's intellectual property portfolio now encompasses over 135 granted or pending patent applications across 23 distinct patent families. The company has exclusively licensed the Gedeptin platform through an agreement with PNP Therapeutics, Inc. and the University of Alabama at Birmingham.
This patent expansion comes as GeoVax prepares to initiate a Phase 2 clinical trial combining Gedeptin with an Immune Checkpoint Inhibitor for patients with first recurrence of head and neck cancer. The new patent claims provide additional protection as the company explores potential partnerships and expanded therapeutic applications.
The innovative approach leverages a non-replicating adenoviral vector encoding a bacterial enzyme that converts a prodrug into a cytotoxic metabolite, offering a potentially more precise cancer treatment mechanism. This method could represent a significant step forward in developing less invasive and more targeted cancer therapies.
